Treatment of migraine headache pain when it is still mild to moderate in intensity improves response and reduces the risk of recurrence. An oral nonopioid analgesic such as a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. When moderate to severe migraine pain is not managed adequately with a nonopioid analgesic alone, addition of a triptan is recommended.

View the Comparison Table: Triptans

View the Comparison Table: Triptans for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.

Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT_1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.